Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Simple item page
dc.contributor.authorNoureddin, Mazen
dc.contributor.authorTruong, Emily
dc.contributor.authorMayo, Rebeca
dc.contributor.authorMartinez-Arranz, Ibon
dc.contributor.authorBanales, Jesus M.
dc.contributor.authorMinchole, Itziar
dc.contributor.authorArrese, Marco
dc.contributor.authorCusi, Kenneth
dc.contributor.authorArias-Loste, Maria Teresa
dc.contributor.authorBruha, Radan
dc.contributor.authorRomero-Gomez, Manuel
dc.contributor.authorIruzubieta, Paula
dc.contributor.authorAller, Rocio
dc.contributor.authorAmpuero, Javier
dc.contributor.authorCalleja, Jose Luis
dc.contributor.authorIbanez-Samaniego, Luis
dc.contributor.authorAspichueta, Patricia
dc.contributor.authorMartin-Duce, Antonio
dc.contributor.authorKushner, Tatyana
dc.contributor.authorOrtiz, Pablo
dc.contributor.authorHarrison, Stephen A.
dc.contributor.authorAnstee, Quentin M.
dc.contributor.authorCrespo, Javier
dc.contributor.authorMato, Jose M.
dc.contributor.authorSanyal, Arun J.
dc.date.accessioned2025-01-20T17:07:02Z
dc.date.available2025-01-20T17:07:02Z
dc.date.issued2024
dc.description.abstractBackground: Early identification of those with NAFLD activity score >= 4 and significant fibrosis (>= F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH.
dc.description.abstractMethods: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE).
dc.description.abstractResults: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4 + MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE (p = 0.69) to identify at-risk MASH.
dc.description.abstractConclusion: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications.
dc.fuente.origenWOS
dc.identifier.doi10.1097/HEP.0000000000000542
dc.identifier.eissn1527-3350
dc.identifier.issn0270-9139
dc.identifier.urihttps://doi.org/10.1097/HEP.0000000000000542
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90832
dc.identifier.wosidWOS:001189733500007
dc.issue.numero1
dc.language.isoen
dc.pagina.final148
dc.pagina.inicio135
dc.revistaHepatology
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSerum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
dc.typeartículo
dc.volumen79
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas